Author: Haire Bridget Kaldor John Jordens Christopher FC
Publisher: Routledge Ltd
ISSN: 1536-0075
Source: American Journal of Bioethics, Vol.12, Iss.6, 2012-06, pp. : 21-30
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
In 2010, randomized controlled trials (RCTs) of two different biomedical strategies to prevent HIV infection had positive findings. However, despite ongoing very high levels of HIV infection in some countries and population groups, it has been made clear by regulatory authorities that the evidence remains insufficient to support either product being made available outside of research contexts in the developing world for at least two years. In addition, prevention trials in endemic areas will continue to test new interventions against placebo. But the judgments of evidentiary standards are never value-neutral. Using the recent trials and their contexts as case studies, we examine the basis for these decisions, which will potentially delay access to scientific innovation to the people who are most urgently in need of it.
Related content
By Ells Carolyn
American Journal of Bioethics, Vol. 1, Iss. 2, 2001-02 ,pp. :
Facilitated Discussion: Good and Good for You
American Journal of Bioethics, Vol. 15, Iss. 1, 2015-01 ,pp. :
By Snyder Jeremy Miller Cari Gray Glenda
American Journal of Bioethics, Vol. 11, Iss. 6, 2011-06 ,pp. :